Alpha 2.0
Login Register
» Authors » Ippei Ikushima

Ippei Ikushima

Explore the profile of Ippei Ikushima including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 15
Citations 93
Followers 0
Related Specialties
Pharmacology
Endocrinology
Cardiology & Vascular Diseases
Top 10 Co-Authors
Akiko Harada
Susumu Imazu
Shin Irie
Joachim Stangier
Masanari Shiramoto
Kyoko Matsuguma
Yoshikazu Kaji
Stephen Norris
Hanne Haahr
Stephan Glund
Published In
J Diabetes Investig
J Atheroscler Thromb
Thromb Haemost
Clin Pharmacol Drug Dev
Ther Innov Regul Sci
Affiliations
Soon will be listed here.
Recent Articles
1.
Effects of concomitant use of prasugrel with edoxaban on bleeding time, pharmacodynamics, and pharmacokinetics of edoxaban in healthy elderly Japanese male subjects: a clinical pharmacology study
Ikushima I, Akasaka T, Morishima Y, Takita A, Motohashi T, Kimura T
Thromb J . 2020 Jun; 18:10. PMID: 32536828
Background: Dual therapy with a direct oral anticoagulant (DOAC) plus a P2Y receptor inhibitor is recommended in patients with nonvalvular atrial fibrillation who undergo percutaneous coronary intervention. Thus, we evaluated...
2.
Pharmacokinetic study of lascufloxacin in non-elderly healthy men and elderly men
Totsuka K, Sesoko S, Fukase H, Ikushima I, Odajima M, Niwayama Y
J Infect Chemother . 2019 Dec; 26(3):231-239. PMID: 31882385
We conducted this phase I clinical study to examine the pharmacokinetic profiles and safety of lascufloxacin (LSFX), a novel quinolone antibacterial agent, in non-elderly Japanese healthy men and the effects...
3.
Bioequivalence of a Newly Developed Dabigatran Etexilate Tablet Versus the Commercial Capsule and Impact of Rabeprazole-Induced Elevated Gastric pH on Exposure in Healthy Subjects
Harada A, Ikushima I, Haranaka M, Yanagihara A, Nakayama D
Am J Cardiovasc Drugs . 2019 Nov; 20(3):249-258. PMID: 31667735
Background And Objective: Dabigatran etexilate (DE) is an anticoagulant with proven efficacy and tolerability for stroke prevention in patients with non-valvular atrial fibrillation. For the commercial capsule, a complex formulation...
4.
Effect of chlorogenic acids on fatigue and sleep in healthy males: A randomized, double-blind, placebo-controlled, crossover study
Ochiai R, Tomonobu K, Ikushima I
Food Sci Nutr . 2018 Dec; 6(8):2530-2536. PMID: 30510754
Chlorogenic acids (CGAs) are found in abundance in coffee beans and have numerous health benefits. This study investigated the effect of CGAs extracted from coffee beans on fatigue and sleep...
5.
Evaluation of Assay Sensitivity and the Concentration-Effect Relationship of Moxifloxacin in a QT/QTc Study in Japan
Shiramoto M, Uchimaru H, Kaji Y, Matsuguma K, Matsuki S, Ikushima I, et al.
Ther Innov Regul Sci . 2018 Sep; 48(2):181-189. PMID: 30227503
To investigate the potential for a QT/QTc study in Japan, a randomized, single-blind, crossover study was conducted using moxifloxacin in 64 healthy Japanese male volunteers. A 12-lead Holter electrocardiogram was...
6.
Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study
Yasaka M, Ikushima I, Harada A, Imazu S, Taniguchi A, Norris S, et al.
Res Pract Thromb Haemost . 2018 Jul; 1(2):202-215. PMID: 30046691
Background: Idarucizumab is a humanized monoclonal antibody fragment that specifically binds with high affinity to dabigatran. Objectives: This study investigated the safety, tolerability and pharmacokinetics of idarucizumab alone and with...
7.
A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects
Ikushima I, Jensen L, Flint A, Nishida T, Zacho J, Irie S
Adv Ther . 2018 Mar; 35(4):531-544. PMID: 29536338
Introduction: Semaglutide is a glucagon-like peptide-1 analogue for once-weekly subcutaneous treatment of type 2 diabetes. This trial compared the pharmacokinetics, pharmacodynamics, and safety of semaglutide in Japanese and Caucasian subjects....
8.
Effects of a Nutritional Protein-Rich Drink on the Pharmacokinetics of Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide, and Tenofovir Compared With a Standard Meal in Healthy Japanese Male Subjects
Yamada H, Ikushima I, Nemoto T, Ishikawa T, Ninomiya N, Irie S
Clin Pharmacol Drug Dev . 2017 Jun; 7(2):132-142. PMID: 28581645
This study investigated the effects of ingested meal types on the pharmacokinetics of elvitegravir (EVG), cobicistat (COBI), emtricitabine (FTC), tenofovir alafenamide (TAF), and tenofovir (TFV) following a single administration of...
9.
Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies
Norris S, Ramael S, Ikushima I, Haazen W, Harada A, Moschetti V, et al.
Br J Clin Pharmacol . 2017 Feb; 83(8):1815-1825. PMID: 28230262
Aims: Idarucizumab, a humanized monoclonal anti-dabigatran antibody fragment, is effective in emergency reversal of dabigatran anticoagulation. Pre-existing and treatment-emergent anti-idarucizumab antibodies (antidrug antibodies; ADA) may affect the safety and efficacy...
10.
Recapitulation of Clinical Individual Susceptibility to Drug-Induced QT Prolongation in Healthy Subjects Using iPSC-Derived Cardiomyocytes
Shinozawa T, Nakamura K, Shoji M, Morita M, Kimura M, Furukawa H, et al.
Stem Cell Reports . 2017 Jan; 8(2):226-234. PMID: 28111276
To predict drug-induced serious adverse events (SAE) in clinical trials, a model using a panel of cells derived from human induced pluripotent stem cells (hiPSCs) of individuals with different susceptibilities...